Biotech · Private company
Atom Therapeutics Co., Ltd
Track this companyFree. Adds Atom Therapeutics Co., Ltd to your Dealase workspace and tells you when its record changes.
Clinical trials91 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline11
- ABP-671Phase 3 · GoutClinicalTrials.gov · fetched Nov 12, 2026
- AllopurinolPhase 3 · GoutClinicalTrials.gov · fetched Nov 12, 2026
- ABP-745 Dose APhase 2 · Acute Gouty ArthritisClinicalTrials.gov · fetched Nov 12, 2026
- ABP-745 Dose APhase 2 · Atherosclerosis Cardiovascular DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ABP-745 Dose BPhase 2 · Atherosclerosis Cardiovascular DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ABP-745 Dose BPhase 2 · Acute Gouty ArthritisClinicalTrials.gov · fetched Nov 12, 2026
- ABP-745 Dose CPhase 2 · Atherosclerosis Cardiovascular DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ColchicinePhase 2 · Acute Gouty ArthritisClinicalTrials.gov · fetched Nov 12, 2026
- ABP-671Phase 1 · HyperuricemiaClinicalTrials.gov · fetched Nov 12, 2026
- ABP-671 plus allopurinolPhase 1 · Gout ChronicClinicalTrials.gov · fetched Nov 12, 2026
- ABP-745Phase 1 · GoutClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials9
- Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With AtherosclerosisPHASE2 · RECRUITING · started Apr 23, 2026ClinicalTrials.gov NCT07303777 · fetched Nov 12, 2026
- Drug-Drug Interaction Study of ABP-671 in Gout PatientsPHASE1 · COMPLETED · started Jan 23, 2026ClinicalTrials.gov NCT07367971 · fetched Nov 12, 2026
- Safety and Efficacy of ABP-745 in Participants With an Acute Gout FlarePHASE2 · COMPLETED · started Aug 26, 2025ClinicalTrials.gov NCT07145229 · fetched Nov 12, 2026
- Extension Study of ABP-671 in Participants With GoutPHASE2_PHASE3 · TERMINATED · started Apr 22, 2024ClinicalTrials.gov NCT06276556 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy VolunteersPHASE1 · COMPLETED · started Jan 23, 2024ClinicalTrials.gov NCT06258213 · fetched Nov 12, 2026
- Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With GoutPHASE2_PHASE3 · COMPLETED · started Aug 11, 2023ClinicalTrials.gov NCT05818085 · fetched Nov 12, 2026
- Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy SubjectsPHASE1 · COMPLETED · started May 22, 2020ClinicalTrials.gov NCT04303039 · fetched Nov 12, 2026
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671PHASE1 · COMPLETED · started Sep 5, 2019ClinicalTrials.gov NCT04060173 · fetched Nov 12, 2026
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy SubjectsPHASE1 · COMPLETED · started Oct 17, 2018ClinicalTrials.gov NCT03906006 · fetched Nov 12, 2026